featured
Second-Line Lisocabtagene Maraleucel vs Standard of Care With Salvage Chemotherapy Followed by Autologous HSCT Transplantation in Relapsed/Refractory LBCL
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
Lancet 2022 Jun 18;399(10343)2294-2308, M Kamdar, SR Solomon, J Arnason, PB Johnston, B Glass, V Bachanova, S Ibrahimi, S Mielke, P Mutsaers, F Hernandez-Ilizaliturri, K Izutsu, F Morschhauser, M Lunning, DG Maloney, A Crotta, S Montheard, A Previtali, L Stepan, K Ogasawara, T Mack, JS Abramson,From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.